



SSO 2027 Annual meeting Abstract Submission Frequently Asked Questions

1. Are there any extensions offered in the submission process?

No, submission extensions are not granted.

2. Can I edit my abstract after submission?

Edits must be sent to SSO staff no later than **November 1** at ssoannualmeeting@surgonc.org as the submission portal will not be accessible.

Revisions permitted until the abstract submission deadline of October 5, 2026:

- All abstract edits
- Author additions or removals

Limited administrative and minor editorial corrections permitted until November 1, 2026:

- spelling, grammar, or formatting corrections
- corrections to author names, degrees, or affiliations
- author order adjustments

The abstract review period begins on October 9, 2026. **No substantive scientific revisions, including changes to data, results, analyses, or conclusions, will be permitted after October 5, 2026.**

The author list submitted by October 5, 2026, is considered final. New authors may not be added, and authors may not be removed after the submission deadline.

Any administrative and minor editorial corrections must be submitted to ssoannualmeeting@surgonc.org **by November 1, 2026**.

3. Is there a fee to submit my abstract?

Yes, a \$60.00 fee is required for each abstract submission and must be paid by credit card at the time of submission.

If you are submitting abstracts to both the SSO 2027 Annual Meeting and the 2027 Advanced Cancer Therapies Conference, only one \$60 fee will apply. A discount code will be provided via email after completing your initial submission.

Please note: The \$60 fee is non-refundable, even if the abstract is withdrawn.

4. Is there a limit to how many abstracts I can submit?

No, there is no limit to the number of abstracts you may submit.

5. Do I have to be an SSO member to submit an abstract?

No, membership is not required. However, at least one author on the abstract should be an SSO member.

Please contact SSO Membership at info@surgonc.org for membership inquiries.

6. Is there a limit to the number of authors you can add to an abstract?

Yes, a maximum of 20 authors is allowed per abstract.

Please note: All abstract revisions, including author additions or removals, must be completed by **October 5, 2026**. After this date, only minor administrative and editorial corrections (e.g., spelling, grammar, formatting, corrections to author names, degrees, affiliations, or author order) may be requested by emailing ssoannualmeeting@surgonc.org no later than **November 1, 2026**.

7. Can I submit an abstract as a Resident/Fellow?

Yes, we encourage residents and fellows to submit abstracts.

8. If my submission is accepted, am I required to register and attend the SSO Annual Meeting to present?

Yes. If your abstract is accepted for any of the following presentation formats, you are required to attend the SSO Annual Meeting in person and register:

- Oral Abstract Presentation
- Video Abstract Presentation
- Quick Shot Poster Presentation
- Poster Park Showcase

9. If my submission is accepted as a Poster, how will it be presented?

Tier 1 – Quick Shot Poster Presentation:

- Abstracts scored in the Tier 1 category will be presented as Quick Shot Poster Presentations in the SSO HUB (Exhibit Hall), organized by disease site zones.
- These presentations will not offer CME credit.
- Presenters will deliver their presentations using an electronic monitor.
- Each presentation will be 3 minutes long, followed by 1 minute for Q&A.
- Individuals selected for Quick Shot Poster Presentations are required to register for and attend the SSO 2027 Annual Meeting.

Tier 2 – Poster Park Showcase:

- Abstracts scored in the Tier 2 category will be featured in the Poster Park Showcase, located in the SSO HUB (Exhibit Hall).
- These presentations will not offer CME credit.
- Presenters are expected to bring their printed copy of their poster and be present at their assigned poster board during designated times scheduled during networking breaks.
- Individuals whose abstracts are selected for display must register for and attend the SSO 2027 Annual Meeting.

Tier 3 – ePoster Gallery:

- Abstracts scored in the Tier 3 category will be included in the SSO 2027 ePoster Gallery.
- No oral presentations will be given.
- ePosters will be available for viewing on electronic kiosks in the SSO 2027 HUB, on the SSO 2027 Meeting Website and the SSO 2027 Mobile App.

- Attendance at the SSO 2027 Annual Meeting is not required for individuals whose abstracts are selected as ePosters.

10. Can I submit an abstract on behalf of a company?

SSO will accept abstract submissions from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies.

PLEASE NOTE: Abstracts should NOT include products or lines of business.

11. Can I submit a Case Report?

Case Reports are only accepted for Video Abstract submissions.

12. Can I submit my abstract to the Advanced Cancer Therapies (ACT) meeting if I submit it to the SSO 2027 Annual Meeting?

Abstracts submitted to ACT can also be submitted and presented at SSO. Dual submission is encouraged.

13. What are the abstract submission publication policies?

When submitting an abstract to the SSO Annual Meeting, the submitting author **must comply** with the following submission policies and is responsible for communicating these policies to all parties involved.

- **Presentation/Publication Prior to the SSO Annual Meeting:**
 - An abstract that has been or will be presented or published at another meeting prior to SSO Annual Meeting can be submitted for presentation if:
 - It was submitted for presentation at:
 - San Antonio Breast Cancer Symposium
 - ASCO GI Cancers Symposium
 - SSO ACT Meeting
 - It is submitted to the SSO Annual Meeting in the **Team Science category** and meets the **Team Science criteria**.
 - **Abstracts accepted, presented or published at any NATIONAL or GLOBAL meetings** (other than those mentioned above) prior to **March 17, 2027**, are **not** eligible for presentation at SSO 2027.

- **SSO will not accept abstracts that represent previously reported studies,** except those submitted in the **Team Science category**.

Team Science Category:

These submissions should highlight work that has been presented or published within 6–12 months prior to the SSO Annual Meeting. Submissions must include full citation of the prior presentation or publication.

14. Are late-breaking abstract submissions accepted?

The SSO late-breaking policy allows for the submission of late-breaking data only for the following:

- You must select the “late breaking” abstract type when submitting your abstract.
- Randomized phase II and III trials with no preliminary data available at the time of the abstract submission deadline (October 5, 2026).
- Original research studies highlight novel and high-impact research with practice-changing implications.

A placeholder (shell) abstract must be submitted by **October 5, 2026**. This must include:

- Background and Methods
- Primary clinical endpoint
- Provide a timeline for data analysis (Type and date of planned analysis)
- Planned statistical methods

Final late-breaking data must be submitted by December 1, 2026, at 11:59 PM CST and must include:

- Results and Conclusions sections.

SSO will send an email requesting final data. **Failure to submit by the deadline will result in abstract removal. No extensions will be granted.**

Review of late-breaking abstracts will begin on December 2, 2026, and conclude on December 8, 2026, at 11:59 PM CST. Notifications will be sent by mid-December 2026.

15.Are trial in progress abstract submissions accepted?

Yes, trials in progress submitted are to be ongoing and have not reached pre-specified endpoints for analysis. As such, inclusion of results is prohibited, and abstracts with results, including secondary endpoints like toxicity or PROs, will not be considered for this session.

Abstracts submissions should include the following:

- **Background**
 - Scientific background/rationale for the trial
 - Preclinical and/or earlier-phase clinical data that has already been publicly presented or published may be included with references.
 - Correlative studies of relevance
- **Methods**
 - Trial design and statistical methods, highlighting any novel aspects of the design
 - Treatment or intervention planned
 - Major eligibility criteria, highlighting unusual aspects
 - Current enrollment without providing results or endpoints
 - **Enrollment must have already begun or completed with no data analysis available by the meeting date.** It is acceptable if the trial is open to enrollment but has not yet enrolled its first patient.
 - **Clinical trial registry number (required)**

Trial-in-Progress abstracts must be submitted by **October 5, 2026, at 11:59 PM CST**. No extensions will be granted.